Oral GLP-1 drugs are expected to capture about 25% of the projected $150 billion obesity market, appealing to patients who prefer pills over injections. Novo Nordisk’s tablet showed strong efficacy, with patients losing an average of 16.6% of body weight in trials, supporting semaglutide’s clinical strength.
For Novo Nordisk, the Wegovy pill offers a critical first-mover advantage amid rising competition. With analysts projecting nearly $2 billion in annual sales by 2030, this approval strengthens NVO’s long-term position in the global obesity market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
